Sign inJoin waitlistJoin the waitlist

Shipra Gandhi

Physician · Emory University School of Medicine

Credentials: · · · · · · ·

History

Emory University School of Medicine
2025–Present

Roswell Park Comprehensive Cancer Center
2015–2018
Internal Medicine
State University of New York
2012–2015
Lady Hardinge Medical College
2006–2010

Research

Adolescent and Young Adult (AYA) Oncology, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2023 · 146 citations
Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor…
Clinical Cancer Research · 2021 · Co-first of 19 authors · Corresponding · 132 citations
Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future
Review · Breast Cancer · 2020 · 125 citations

Kazuaki Takabe
29 papers
AR
Arya Roy
19 papers · 19 as a fellow
Song Yao
17 papers · 1 as a resident
Thaer Khoury
12 papers
AP
Archit Patel
6 papers · 2 as a fellow
Ajay Dhakal
5 papers
Ankita Kapoor
5 papers · 5 as a resident
Ellis Levine
5 papers
MA
Malak Alharbi
5 papers
Marc Ernstoff
5 papers
SA
Sabah Alaklabi
5 papers
TO
Tracey O’Connor
5 papers

Grants

Stress-Induced Immunosuppression via Downregulation of Interferon in Triple Negative Breast Cancer
National Cancer Institute · K08
Contact PI · $915K · Emory University
2024–2029
Identifying the Role of Interferon and Interferon-Regulated Chemokines in Stress-Induced Immunosuppression in Triple Negative Breast Cancer
National Center for Advancing Translational Sciences · R03
Contact PI · $173.5K · Roswell Park Cancer Institute Corp
2023–2025

Clinical trials

Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer
Principal investigator · Withdrawn · Phase 2
Roswell Park Cancer Institute
2025–2027
Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
Principal investigator · Recruiting · Phase 2
Emory University
2024–2029
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
Principal investigator · Completed · Phase 1
Roswell Park Cancer Institute
2019–2023
Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer
Principal investigator · Completed · Early phase 1
Roswell Park Cancer Institute
2019–2023